Scardillo Alessio, Pugliese Michela, De Majo Massimo, Niutta Pietro P, Pugliese Antonio
Department of Veterinary Public Health, Veterinary Medicine Faculty, University of Messina, Italy.
Vet Ther. 2010 Fall;11(3):E1-6.
The goal of glaucoma management is to reduce intraocular pressure (IOP) and maintain it at a level compatible with the health of the optic nerve. New therapies are constantly being sought. Topical instillation of levobunolol 0.5%, alone or with dorzolamide 2%, has a hypotensive effect on the IOP in healthy dogs, and levobunolol combined with dorzolamide produces a stronger hypotensive effect than the combination of timolol and dorzolamide. All animals tolerate these topical medications well with no signs of discomfort, and no ocular side effects have been observed. Levobunolol, alone or in combination with dorzolamide, induces bradycardia, as does timolol with dorzolamide.
青光眼治疗的目标是降低眼压（IOP）并将其维持在与视神经健康相适应的水平。人们一直在寻找新的治疗方法。局部滴注0.5%的左布诺洛尔，单独使用或与2%的多佐胺联合使用，对健康犬的眼压有降压作用，且左布诺洛尔与多佐胺联合使用产生的降压作用比噻吗洛尔与多佐胺联合使用更强。所有动物对这些局部用药耐受性良好，没有不适迹象，也未观察到眼部副作用。左布诺洛尔单独使用或与多佐胺联合使用会诱发心动过缓，噻吗洛尔与多佐胺联合使用也会如此。
